Potassium oxonate

• Description :

  Potassium oxonate (Potassium azaorotate) is a uricase inhibitor that inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate.

• Product Name Alternative :

  Potassium azaorotate; Potassium otastat; Oteracil potassium

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Xanthine Oxidase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/Oxonic-acid-potassium-salt.html

• Purity :

  99.94

• Solubility :

  DMSO : < 1 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(O[K])C1=NC(O)=NC(O)=N1

• Molecular Formula :

  C4H2KN3O4

• Molecular Weight :

  195.17

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Shirasaka T, et al. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993 Sep 1;53 (17) :4004-9.|[2]Eraranta A, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008 Aug;26 (8) :1661-8.|[3]Yoshisue K, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos. 2000 Oct;28 (10) :1162-7.|[4]Chen Y, et al. Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Biomed Pharmacother. 2019 Oct;118:109195.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2207-75-2]